Form 8-K - Current report:
SEC Accession No. 0000950170-22-011724
Filing Date
2022-06-16
Accepted
2022-06-16 09:00:15
Documents
14
Period of Report
2022-06-15
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ktra-20220615.htm   iXBRL 8-K 77956
2 EX-99.1 ktra-ex99_1.htm EX-99.1 19157
3 GRAPHIC img40499469_0.jpg GRAPHIC 115627
  Complete submission text file 0000950170-22-011724.txt   387710

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ktra-20220615_pre.xml EX-101.PRE 11495
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ktra-20220615.xsd EX-101.SCH 2471
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ktra-20220615_lab.xml EX-101.LAB 18302
8 EXTRACTED XBRL INSTANCE DOCUMENT ktra-20220615_htm.xml XML 4690
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

EIN.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 221019413
SIC: 2834 Pharmaceutical Preparations